Subtilisin NAT · Natto Extract · Fermented Soybean Enzyme
2,000 FU · vegan · gluten-free · 90 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Nattokinase is a serine protease enzyme extracted from natto, a traditional Japanese fermented soybean product. It was discovered by Dr. Hiroyuki Sumi in 1980 and has been marketed for cardiovascular health, blood pressure reduction, and fibrinolytic activity.
In vitro and animal studies show nattokinase directly cleaves fibrin and activates plasminogen to plasmin, the body's endogenous fibrinolytic enzyme. It may also inhibit angiotensin-converting enzyme (ACE), contributing to blood pressure reduction. However, these mechanisms are primarily demonstrated in laboratory settings and animal models — human in vivo fibrinolytic effects at standard oral doses are less well-characterized.
Adults with mild elevated blood pressure seeking adjunctive support · those interested in fermented food-derived supplements with realistic expectations · NOT for anyone with bleeding disorders, on anticoagulants, or seeking clot prevention as a substitute for medically indicated therapy.
Bleeding disorders or concurrent anticoagulant/antiplatelet therapy (warfarin, aspirin, clopidogrel, DOACs) · upcoming surgery (discontinue 2 weeks prior) · pregnancy/lactation (insufficient safety data) · severe hypotension · do not use as replacement for statins, antihypertensives, or anticoagulants prescribed for cardiovascular disease.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Empty stomach, divided doses
✓ Empty stomach, divided doses
✓ Take on empty stomach for better absorption; food may reduce protease activity
In vitro and animal studies show nattokinase directly cleaves fibrin and activates plasminogen to plasmin, the body's endogenous fibrinolytic enzyme.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Stage 1 hypertension cohort (n≈70)
Target systolic BP <130 mmHg (ACC/AHA 2017 guidelines).
see study
→ 86 participants with pre-hypertension or stage 1 hypertension: nattokinase 2,000 FU/day for 8 weeks reduced systolic BP by 5.55 mmHg and diastolic BP by 2.84 mmHg vs placebo, with reduced renin activity.
see study
→ Review of human trials: nattokinase showed modest BP reduction, fibrinogen lowering, and antithrombotic effects in small studies; called for larger RCTs to confirm cardiovascular outcomes.
see study
→ Review of mechanisms and trials: nattokinase has antihypertensive, anticoagulant, and fibrinolytic effects in vitro and in small human studies, but large-scale clinical outcome trials are lacking.
C · C+ for blood pressure reduction (small RCT, ~5 mmHg systolic reduction). D for fibrinolytic/clot-prevention claims — these are based on in vitro assays and enzyme activity, not human outcome trials. No trial has demonstrated reduced stroke, MI, or DVT with nattokinase supplementation. The marketing significantly exceeds the evidence.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 19567386 (Sumi 1987, discovery paper), PMID 26896469 (Kurosawa 2015, blood pressure RCT), PMID 25157668 (Chen 2013, fibrinolytic activity study).
How to use Nattokinase specifically for Elevated blood pressure — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Nattokinase — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Nattokinase — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Nattokinase — context the structured blocks above don't capture.
Nattokinase is the supplement industry’s favorite example of how in vitro enzyme activity assays become human health claims without the intervening trial evidence. The fibrinolytic mechanism is real in a petri dish: nattokinase cleaves fibrin and activates plasminogen. The blood pressure reduction is real in a small human trial: ~5 mmHg systolic drop in pre-hypertensive individuals. But the leap from these findings to “prevents blood clots” and “natural alternative to blood thinners” is a marketing extrapolation that the evidence does not support.
The mechanism has two claimed components. First, fibrinolysis: nattokinase is a serine protease that, in laboratory conditions, directly degrades fibrin clots and converts plasminogen to plasmin. Second, blood pressure: nattokinase appears to inhibit ACE and reduce renin activity, similar to the mechanism of ACE inhibitor medications. Both mechanisms are biologically plausible and demonstrated in vitro and in animal models. The critical question is whether oral doses of nattokinase produce clinically meaningful effects on human thrombosis or cardiovascular outcomes.
The human trial evidence is thin. Kim et al. (2008) randomized 86 participants with pre-hypertension or stage 1 hypertension to nattokinase 2,000 FU/day or placebo for 8 weeks. The nattokinase group had a net reduction of 5.55 mmHg systolic and 2.84 mmHg diastolic blood pressure compared to placebo, with a concurrent reduction in plasma renin activity. This is a real, statistically significant effect — but it is a single small trial, and the effect size is modest compared to lifestyle interventions (weight loss, sodium restriction, exercise) or first-line antihypertensives.
The fibrinolytic claims are the most overstated. Multiple reviews (Chen et al., 2022; Jang et al., 2016) summarize the in vitro and animal data comprehensively and then note, uniformly, that large-scale human clinical outcome trials are lacking. No randomized trial has tested whether nattokinase reduces stroke, myocardial infarction, deep vein thrombosis, or pulmonary embolism. The “fibrinolytic units” (FU) on labels are manufacturer-specific activity assays measured in vitro — they do not translate to in vivo clot dissolution. A supplement that dissolves fibrin in a test tube at pH 7.4 does not necessarily dissolve clots in the human circulation after passing through the stomach, liver, and systemic metabolism.
The honest framing: nattokinase has modest blood pressure evidence from one small trial. It is not a treatment for hypertension. It is not a substitute for anticoagulants in atrial fibrillation, post-stroke prevention, or DVT prophylaxis. The fibrinolytic marketing is based on laboratory assays, not human outcome data. If you have cardiovascular disease, take prescribed medications. If you have mild elevated blood pressure and want to try nattokinase as an adjunct, do so with realistic expectations and monitor your blood pressure.
Practical guidance: 2,000-4,000 FU daily, on an empty stomach. Start at the lower end. Monitor blood pressure if using for hypertension support. Do not combine with warfarin, aspirin, clopidogrel, or any anticoagulant — the bleeding risk is real and unquantified. Discontinue 2 weeks before surgery. If you experience unusual bruising, nosebleeds, or prolonged bleeding, stop immediately and seek medical attention.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
